EU‐OPENSCREEN ‐ Innovative collaboration models for molecular biologists in early drug discovery

Collaboration for rare disease drug discovery research

Rare disease research has reached a tipping point, with the confluence of scientific and technologic developments that if appropriately harnessed, could lead to key breakthroughs and treatments for this set of devastating disorders. Industry-wide trends have revealed that the traditional drug discovery research and development (R&D) model is no longer viable, and drug companies are evolving the...

Innovative Partnerships for Drug Discovery against Neglected Diseases

There is a compelling scarcity of pharmaceutical agents for efficacious, safe, and affordable treatment of neglected infectious or tropical diseases such as malaria, trypanosomiasis, leishmaniasis, dengue, lymphatic filariasis, and soiltransmitted helminths, despite their high prevalence in the developing world. Toxicity of drugs, microbial resistance patterns, and long courses of treatments ar...

An expanding role for cell biologists in drug discovery and pharmacology

The profound challenges facing clinicians, who must prescribe drugs in the face of dramatic variability in response, and the pharmaceutical industry, which must develop new drugs despite ever-rising costs, represent opportunities for cell biologists interested in rethinking the conceptual basis of pharmacology and drug discovery. Much better understanding is required of the quantitative behavio...

Finding New Collaboration Models for Enabling Neglected Tropical Disease Drug Discovery

Neglected tropical diseases (NTDs) have seen a welcome bolstering of activities focused on discovery of new therapies for these diseases. By and large, NTD drug discovery happens in the nonprofit sector—in academic laboratories and in public–private partnerships—though there has also been a significant and tangible influx of data and research contributions from the for-profit biopharmaceutical ...

***Removed from the Issue*** Application of Cell-Based Assay Systems for the Early Screening of Human Drug Hepatotoxicity in the Discovery Phase of Drug Development